Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01602-25 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Sara M Karaba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Ceftazidime, Boronic Acids, Meropenem, Azabicyclo Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Prevention Epicenters Program of the Centers for Disease Control and Prevention, NIAID NIH HHS.
Abstract (Originalsprache)
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations ( Klebsiella pneumoniae ) and R2 loop structural changes in AmpC ( Enterobacter cloacae complex).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Sara M Karaba, Jose M Munita, Jose R W Martinez, Zackery P Bulman, Patricia J Simner, Pranita D Tamma
Förderung
- NIH HHS
- Prevention Epicenters Program of the Centers for Disease Control and Prevention
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Karaba, S. M., Hareza, D. A., Munita, J. M., Martinez, J. R. W., Bergman, Y., Hawes, A. M., Bulman, Z. P., Cosgrove, S. E., Simner, P. J., & Tamma, P. D. (2026). Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01602-25
Vancouver
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, et al. Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01602-25
BibTeX
@article{Karaba2026,
author = {Karaba, Sara M and Hareza, Dariusz A and Munita, Jose M and Martinez, Jose R W and Bergman, Yehudit and Hawes, Armani M and Bulman, Zackery P and Cosgrove, Sara E and Simner, Patricia J and Tamma, Pranita D},
title = {Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01602-25}
}
EUVIMED